Кардиоваскулярная безопасность коксибов


DOI: https://dx.doi.org/10.18565/therapy.2023.4.58-65

Л.З. Болиева, Т.В. Адашева, М.Д. Даурова

1) ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Минздрава России, г. Владикавказ; 2) ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России
Аннотация. Нестероидные противовоспалительные препараты (НПВП) – одни из наиболее часто используемых лекарственных средств. Основным механизмом действия препаратов этой группы является ингибирование циклооксигеназы (ЦОГ). С этим механизмом связывают не только терапевтические эффекты НПВП, но и неблагоприятные лекарственные реакции при их применении, в частности повышение кардиоваскулярного риска. Целью настоящего обзора стало обобщение имеющихся к настоящему времени данных о сердечно-сосудистой безопасности высокоселективных ингибиторов ЦОГ-2 коксибов. Показано, что кардиоваскулярные побочные эффекты являются класс-специфическими для НПВП и не зависят от селективности в отношении ЦОГ-2. В целом коксибы имеют сопоставимую с неселективными НПВП кардиоваскулярную безопасность при лучшем профиле безопасности со стороны желудочно-кишечного тракта. В то же время существуют определенные различия между препаратами по влиянию на артериальное давление, сердечный ритм, сердечную недостаточность, частоту фатальных и нефатальных кардиоваскулярных событий.
Ключевые слова: кардиоваскулярная безопасность, коксибы, нестероидные противовоспалительные препараты
Полный текст статьи доступен
в "Библиотеке Врача"

Литература

1. Пахомова И.Г. НПВП-ассоциированные повреждения желудочно-кишечного тракта и их осложнения: пути профилактики. Consilium Medicum. 2017; 19(9): 109–113.


2. Hawkey C.J. COX-2 chronology. Gut. 2005; 54(11): 1509–14. https://dx.doi.org/10.1136/gut.2005.065003.


3. Van Hecken A., Schwartz J., Depre M. et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000; 40(10): 1109–20. https://dx.doi.org/10.1177/009127000004001005.


4. Capone M., Tacconelli S., Sciulli M., Patrignani P. Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol. Pharmacol. 2003; 16(2 Suppl.): 49–58.


5. Singh G., Fort J., Goldstein J. et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006; 119(3): 255–66. https://dx.doi.org/10.1016/j.amjmed.2005.09.054.


6. Cannon C., Curtis S., FitzGerald G. et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet. 2006; 368(9549): 1771–81. https://dx.doi.org/10.1016/S0140-6736(06)69666-9.


7. Hunt R., Harper S., Watson D. et al. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. Am J Gastroenterol. 2003; 98(8): 1725–33.https://dx.doi.org/10.1111/j.1572-0241.2003.07598.x.


8. Laine L., Curtis S.P., Cryer B. et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: A randomised comparison. Lancet. 2007; 369(9560): 465–73. https://dx.doi.org/10.1016/S0140-6736(07)60234-7.


9. Silverstein F., Faich G., Goldstein J. et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 2000; 284(10): 1247–55. https://dx.doi.org/10.1001/jama.284.10.1247.


10. Chan F., Lanas A., Scheiman J. et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet. 2010; 376(9736): 173–79. https://dx.doi.org/10.1016/S0140-6736(10)60673-3.


11. Moore R., Derry S., Makinson G., McQuay H. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: Systemic review and meta-analysis on information from company clinical reports. Arthritis Res Ther. 2005; 7(3): R644–65. https://dx.doi.org/10.1186/ar1704.


12. Bresalier R., Sandler R., Quan H. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005; 352(11): 1092–102. https://dx.doi.org/10.1056/NEJMoa050493.


13. Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000; 343(21): 1520–28. https://dx.doi.org/10.1056/NEJM200011233432103.


14. Horton R. Vioxx, the implosion of Merck, and aftershocks at the FDA. Lancet. 2004; 364(9450): 1995–96.https://dx.doi.org/10.1016/S0140-6736(04)17523-5.


15. Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ. 2004; 329(7478): 1308.https://dx.doi.org/10.1136/bmj.329.7478.1308.


16. Ott E., Nussmeier N.A., Duke P.C. et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003; 125(6): 1481–92.https://dx.doi.org/10.1016/s0022-5223(03)00125-9.


17. Nussmeier N., Whelton A., Brown M. et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005; 352(11): 1081–91. https://dx.doi.org/10.1056/NEJMoa050330.


18. Melnikova I. Future of COX 2 inhibitors. Nat Rev Drug Discov. 2005; 4(6): 453–54. https://dx.doi.org/10.1038/nrd1755.


19. Patrignani P., Tacconelli S., Bruno A. et al. Managing the adverse effects of nonsteroidal anti-inflammatory drugs. Expert Rev Clin. Pharmacol. 2011; 4(5): 605–21. https://dx.doi.org/10.1586/ecp.11.36.


20. Hocherl K., Endemann D., Kammerl M.C. et al. Cyclo-oxygenase-2 inhibition increases blood pressure in rats. Br J Pharmacol. 2002; 136(8): 1117–26. https://dx.doi.org/10.1038/sj.bjp.0704821.


21. Qi Z., Hao C.M., Langenbach R.I. et al. Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II. J Clin Invest. 2002; 110(1): 61–69. https://dx.doi.org/10.1172/JCI14752.


22. Bulut D., Liaghat S., Hanefeld C. et al. Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension. J Hypertens. 2003; 21(9): 1663–67.https://dx.doi.org/10.1097/00004872-200309000- 00015


23. Fosbol E.L., Folke F., Jacobsen S. et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes. 2010; 3(40): 395–405.https://dx.doi.org/10.1161/CIRCOUTCOMES.109. 861104.


24. Sudano I., Flammer A.J., Roas S. et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and hypertension. Curr Hypertens Rep. 2012; 14(4): 304–9. https://dx.doi.org/10.1007/s11906-012-0274-7.


25. Liew J.W., Ward M.M., Reveille J.D. et al. Nonsteroidal anti-inflammatory drug use is associated with incident hypertension in ankylosing spondylitis. Аrthritis Care Res. 2020; 72(11): 1645–52. https://dx.doi.org/10.1002/acr.24070.


26. Mitchell J.A., Kirkby N.S. Eicosanoids, prostacyclin and cyclooxygenase in the cardiovascular system. Br J Pharmacol. 2019; 176(8): 1038–50. https://dx.doi.org/10.1111/bph.14167.


27. Cheng H.F., Harris R.C. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004; 43(3): 525–30.https://dx.doi.org/10.1161/01. HYP.0000116221.27079.


28. Bertagnolli M.M., Eagle J. Craig, Zauber A.G. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006; 355(9): 873–84. https://dx.doi.org/10.1056/NEJMoa061355.


29. Schwartz J.I., Tach C., Lasseter K.C. et al. Efects of etoricoxib and comparator nonsteroidal anti-infammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly subjects consuming a controlled sodium diet. Clinical Pharmacol. 2007; 47(12): 1521–31. https://dx.doi.org/10.1177/0091270007307878.


30. Sowers J.R., White W.B., Pitt B.et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-infammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005; 165(2): 161–68. https://dx.doi.org/10.1001/archinte.165.2.161.


31. Ruschitzka F., Borer J.S., Krum H. et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial. Eur Heart J. 2017; 38(44): 3282–92. https://dx.doi.org/10.1093/eurheartj/ehx508.


32. Zhang J., Ding E.L., Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: Meta-analysis of randomized trials. JAMA. 2006; 296(13): 1619–32. https://dx.doi.org/10.1001/jama.296.13.jrv60015.


33. Chan C.C., Reid C.M., Aw T.-J. et al. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009; 27(12): 233 –41. https://dx.doi.org/10.1097/HJH.0b013e3283310dc9.


34. Krum H., Swergold G., Curtis S.P. et al. Factors associated with blood pressure changes in patients receiving diclofenac or etoricoxib: Results from the MEDAL study. J Hypertens. 2009; 27(4): 886–93. https://dx.doi.org/10.1097/HJH.0b013e328325d831.


35. Merck Sharp & Dohme Ltd. Arcoxia 30, 60, 90, 120 mg flmcoated tablets


36. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Аркоксиа. РУ: ЛП-№(000508)-(РГ-RU) от 10.11.2022. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8dc6aa35-d3cb-4481-8319-133fb69708dd (дата обращения – 01.05.2023).


37. Accord-UK Ltd. Diclofenac potassium 50 mg tablets prescribing information. 2017.URL: https://www.medicines.org.uk/emc/ product/4515/smpc (date of access – 01.05.2023).


38. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Вольтарен. РУ: П N015266/01 от 14.03.2018. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=0d8e9f05-2494-405a-b1c7-9cb02c510324 (дата обращения – 01.05.2023).


39. Pfizer Ltd. Celebrex 100 mg capsule


40. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Целебрекс. РУ: ЛП-002118 от 13.10.2022. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f6829510-dc1a-4ff3-85d7-b986ae5bdb2e (дата обращения – 01.05.2023).


41. Chenevard R., Hurlimann D., Bechir M. et al. Selective COX2 inhibition improves endothelial function in coronary artery disease. Circulation. 2003; 107(3): 405–9. https://dx.doi.org/10.1161/01.CIR.0000051361.69808.3A.


42. Walter M.F., Jacob R.F., Day C.A. et al. Sulfone COX-2 inhibitors increase susceptibility of human LDL and plasma to oxidative modifcation: Comparison to sulfonamide COX-2 inhibitors and NSAIDs. Atherosclerosis. 2004; 177(2): 235–43.https://dx.doi.org/10.1016/j.atherosclerosis.2004.10.001.


43. Widlansky M.E., Price D.T., Gokce N. et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension. 2003; 42(3): 310–15. https://dx.doi.org/10.1161/01.HYP.0000084603.93510.28.


44. Arfe A., Scotti L., Varas-Lorenzo C. et al. Non-steroidal antiinflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016; 354: i4857. https://dx.doi.org/10.1136/bmj.i4857.


45. Hudson M., Richard H., Pilote L. Different in outcome of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: Population based study. BMJ. 2005; 330(7504): 1370. https://dx.doi.org/10.1136/bmj.330.7504.1370


46. Bernatsky S., Hudson M., Suissa S. Anti-rheumatic drug use and risk of hospitalisation for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford). 2005; 44(5): 677–80. https://dx.doi.org/10.1093/rheumatology/keh610.


47. Mamdani M., Juurlink D.N., Lee D.S. et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in eldery patients: A population-based cohort study. Lancet. 2004; 363(9423): 1751–56.https://dx.doi.org/10.1016/S0140-6736(04)16299-5.


48. Ungprasert P., Srivali N., Thongprayoon C. Nonsteroidal antiinflammatory drugs and risk of incident heart failure: A systematic review and meta-analysis of observational studies. Clin Cardiol. 2016; 39(2): 111–18. https://dx.doi.org/10.1002/clc.22502.


49. Scott P.A., Kingsley G.H., Scott D.L. Non-steroidal anti-inflammatory drugs and cardiac failure: Meta-analyses of observational studies and randomised controlled trials. Eur J Heart Fail. 2008; 10(11): 1102–7. https://dx.doi.org/10.1016/j.ejheart.2008.07.013.


50. Harirforoosh S., Asghar W., Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: An update of gastrointestinal, cardiovascular and renal complications. J Pharm Sci. 2013; 16(5): 821–47. https://dx.doi.org/10.18433/J3VW2F.


51. Grosser T., Fries S., FitzGerald G.A. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenes an opportunities. J Clin Invest. 2006; 116(1): 4–15. https://dx.doi.org/10.1172/JCI27291.


52. Schaeverbeke T., Heloire F., Deray G.


53. Back M., Yin L., Ingelsson E. Cyclooxygenase-2 inhibitors and cardiovascular risk in a nation-wide cohort study after the withdrawal of rofecoxib. Eur. Heart J. 2012; 33(15): 1928–33. https://dx.doi.org/10.1093/eurheartj/ehr421.


54. Schmidt M., Christiansen C.F., Mehnert F. et al. Non-steroidal anti-inflammatory drug use and risk of atrial fibrillation or flutter: Population based case-control study. BMJ. 2011; 343: d3450. https://dx.doi.org/10.1136/bmj.d3450.


55. Cheng Y., Austin S.C., Rocca B. et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002; 296(5567): 539–41. https://dx.doi.org/10.1126/science.1068711.


56. Catella-Lawson F., Reilly M.P., Kapoor S.C. et al. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med. 2001; 345(25): 1809–17. https://dx.doi.org/10.1056/NEJMoa003199.


57. Capone M.L., Sciulli M.G., Tacconelli S. et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005; 45(8): 1295–301. https://dx.doi.org/10.1016/j.jacc. 2005.01.045.


58. Wilner K.D., Rushing M., Walden C. et al. Celecoxib does not affect the antiplatelet activity of aspirin in healthe volunteers. J Clin Pharmacol. 2002; 42(9): 1027–30. https://dx.doi.org/10.1177/ 0091270002042009010.


59. Laine L., White W.B., Rostom A., Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum. 2008; 38(3): 165–87. https://dx.doi.org/10.1016/j.semarthrit.2007. 10.004.


60. Vonkeman H.E., Brouwers J.R., van de Laar M.A. Understanding the NSAID related risk of vascular events. BMJ. 2006; 332(7546): 895–98. https://dx.doi.org/10.1136/bmj.332.7546.895.


61. Fosbol E.L., Kober L., Torp-Pedersen C., Gislason G.H. Cardiovascular safety of non-steroidal anti-inflammatory drugs among healthy individuals. Expert Opin Drug Saf. 2010; 9(6): 893–903. https://dx.doi.org/10.1517/14740338.2010.501331


62. Gislason G.H., Jacobsen S., Rasmussen J.N. et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006; 113(25): 2906–13. https://dx.doi.org/10.1161/CIRCULATIONAHA.106.616219.


63. Schjerning Olsen A.M., Gislason G.H., McGettigan P. et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA. 2015; 313(8): 805–14.https://dx.doi.org/10.1001/jama.2015.0809.


64. Masclee G.M.C., Straatman H., Arfe A. et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project. PLoS One. 2018; 13(11): 0204746. https://dx.doi.org/10.1371/journal.pone.0204746.


65. Bhala N., Emberson J., Merhi A. Vascular and upper gastrointestinal efects of non-steroidal anti-infammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet. 2013; 382(9894): 769–79.https://dx.doi.org/10.1016/S0140-6736(13)60900-9.


66. Trelle S., Reichenbach S., Wandel S. et al. Cardiovascular safety of non-steroidal anti-infammatory drugs: Network metaanalysis. BMJ. 2011; 342: c7086. https://dx.doi.org/10.1136/bmj.c7086.


67. McGettigan P., Henry D. Cardiovascular risk with non-steroidal anti-infammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med. 2011; 8(9): e1001098. https://dx.doi.org/10.1371/journal.pmed.1001098.


68. White W.B., Faich G., Whelton A. et al. Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specifc inhibitor, versus ibuprofen or diclofenac. Am J Cardiol. 2002; 89(4): 425–30. https://dx.doi.org/10.1016/s0002-9149(01)02265-2.


69. Nissen S.E., Yeomans N.D., Solomon D.H. et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016; 375(26): 2519–29. https://dx.doi.org/10.1056/NEJMoa1611593.


70. Strand V. Are COX-2 inhibitors preferable to non-selective nonsteroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin? Lancet. 2007; 370(9605): 2138–51. https://dx.doi.org/10.1016/S0140-6736(07)61909-6.


71. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. с соавт. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56(Прил. 1): 1–29. 


Об авторах / Для корреспонденции

Лаура Зелимхановна Болиева, д.м.н., профессор, зав. кафедрой фармакологии с клинической фармакологией ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Минздрава России. Адрес: 362019, Владикавказ, ул. Пушкинская, д. 40. E-mail: bolievalz@mail.ru. ORCID: https://orcid.org/0000-0002-3763-8994
Татьяна Владимировна Адашева, д.м.н., профессор кафедры терапии и профилактической медицины ФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава России. Адрес: 107150, Москва, ул. Лосиноостровская, д. 39, стр. 1. E-mail: adashtv@mail.ru. ORCID: https://orcid.org/0000-0002-3763-8994
Мадина Даурбековна Даурова, к.м.н., доцент кафедры фармакологии с клинической фармакологией ФГБОУ ВО «Северо-Осетинская государственная медицинская академия» Минздрава России. Адрес: 362019, Владикавказ, ул. Пушкинская, д. 40. E-mail: daurovamadina@yandex.ru


Похожие статьи

К содержанию номера

Бионика Медиа